יומירה 40 מ"ג

País: Israel

Língua: hebraico

Origem: Ministry of Health

Ingredientes ativos:

ADALIMUMAB 40 MG / 0.8 ML

Disponível em:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

Código ATC:

L04AA17

Forma farmacêutica:

SOLUTION FOR INJECTION

Composição:

PEN

Via de administração:

S.C

Fabricado por:

ABBVIE LTD, UK

Grupo terapêutico:

ADALIMUMAB

Indicações terapêuticas:

* Rheumatoid arthritis: Humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray adn to impove physical function when given in combination with methotrexate. * Crohn's disease : Humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy.Humira is indicated for reducing signs and symptoms and inducing clinical r

Data de autorização:

2009-07-01